It has been hypothesized that combining conventional treatments with FOXO3a agonists may induce the expression of FOXO3a-related death genes, and may thus increase the anti-tumor effects of sorafenib in PTEN-deficient and androgen independent prostate cancer. This evidence concerns the gene PTEN and prostate carcinoma.